LFTD Partners (LIFD) 10-K 13 Mar 19 2018 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2018	Feb. 12, 2019	Jun. 30, 2018
Document and Entity Information:
Registrant Name	ACQUIRED SALES CORP.
Registrant CIK	0001391135
SEC Form	10-K
Period End date	Dec. 31, 2018
Fiscal Year End	--12-31
Trading Symbol	aqsp
Tax Identification Number (TIN)	870479286
Number of common stock shares outstanding		2,369,648
Public Float			$ 314,633
Filer Category	Non-accelerated Filer
Entity a Well-known Seasoned Issuer	No
Entity a Voluntary Filer	No
Entity's Reporting Status Current	Yes
Entity Small Business	true
Voluntary filer	No
Well-known Seasoned Issuer	No
Emerging Growth Company	false
Ex Transition Period	false
Entity Shell Company	false
Amendment Flag	false
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	FY
Entity Incorporation, State Country Name	Nevada
Entity Address, Address Line One	31 N. Suffolk Lane, Lake Forest, Illinois
Entity Address, Postal Zip Code	60045

BALANCE SHEETS

BALANCE SHEETS - USD ($)	Dec. 31, 2018	Dec. 31, 2017
ASSETS
Total Assets	$ 0	$ 0
Accounts Payable - Related Party
Accounts Payable - Related Party - Payable to William C. Jacobs	164,417	103,907
Accounts Payable - Related Party - Payable to Gerard M. Jacobs	24,583	13,841
Accounts Payable - Related Party - Payable to Other Related Party	4,000	4,000
Accounts Payable - Related Party	193,000	121,748
Notes Payable - Payable to Joshua A. Bloom	20,025	0
Notes Payable - Payable to Gerard M. Jacobs	10,766	0
Notes Payable - Related Party	30,791	0
Interest - Payable to Joshua A. Bloom	914	0
Interest - Payable to Gerard M. Jacobs	467	0
Interest Payable - Related Party	1,381	0
Trade Accounts Payable	113,450	106,426
Total Current Liabilities	338,622	228,174
Commitments and Contingencies	0	0
Shareholders' Equity
Preferred stock, $0.001 par value; 10,000,000 shares authorized; none outstanding	0	0
Common stock, $0.001 par value; 100,000,000 shares authorized; 2,369,648 shares outstanding, respectively	2,370	2,370
Additional paid-in capital	13,664,697	13,554,524
Accumulated Deficit	(14,005,689)	(13,785,068)
Total Shareholders' Equity (Deficit)	(338,622)	(228,174)
Total Liabilities and Shareholders' Equity	$ 0	$ 0

BALANCE SHEETS (Parenthetical)

BALANCE SHEETS (Parenthetical) - $ / shares	Dec. 31, 2018	Dec. 31, 2017
Statement of Financial Position [Abstract]
Preferred Stock, par or stated value	$ 0.001	$ 0.001
Preferred Stock, shares authorized	10,000,000	10,000,000
Preferred Stock, shares outstanding	0	0
Common Stock, par or stated value	$ 0.001	$ 0.001
Common Stock, shares authorized	100,000,000	100,000,000
Common Stock, shares outstanding	2,369,648	2,369,648

STATEMENTS OF OPERATIONS

STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Income Statement [Abstract]
Selling, General and Administrative Expense	$ (71,299)	$ (65,021)
Stock Compensation Expense	72,500	0
Professional Fees	(37,767)	(15,012)
Interest Expense	(39,055)	0
Provision for Income Taxes	0	0
Net Loss	$ (220,621)	$ (80,033)
Basic and Diluted Earnings (Loss) per Share	$ (0.09)	$ (0.03)
Basic and diluted weighted average number of common shares outstanding:	2,369,648	2,369,648

STATEMENTS OF SHAREHOLDERS' EQU

STATEMENTS OF SHAREHOLDERS' EQUITY (DEFICIT) - USD ($)	Common Stock	Additional Paid-In Capital	Retained Earnings / Accumulated Deficit	Total
Stockholders' Equity Attributable to Parent, Beginning Balance at Dec. 31, 2016	$ 2,370	$ 13,554,524	$ (13,705,035)	$ (148,141)
Shares, Outstanding, Beginning Balance at Dec. 31, 2016	2,369,648
Stock Compensation Expense				0
Net Loss	$ 0	0	(80,033)	(80,033)
Stockholders' Equity Attributable to Parent, Ending Balance at Dec. 31, 2017	$ 2,370	13,554,524	(13,785,068)	(228,174)
Shares, Outstanding, Ending Balance at Dec. 31, 2017	2,369,648
Stock Compensation Expense		72,500		72,500
Issuance of warrants to purchase common stock		37,673		37,673
Net Loss	$ 0	0	(220,621)	(220,621)
Stockholders' Equity Attributable to Parent, Ending Balance at Dec. 31, 2018	$ 2,370	$ 13,664,697	$ (14,005,689)	$ (338,622)
Shares, Outstanding, Ending Balance at Dec. 31, 2018	2,369,648

STATEMENTS OF CASH FLOWS

STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Cash Flows From Operating Activities
Net Loss	$ (220,621)	$ (80,033)
Adjustments to Reconcile Loss to Net Cash Used in Operating Activities:
Stock Compensation Expense	72,500	0
Financing Cost - Issuance of Warrants to Purchase Common Stock	37,673	0
Changes in Operating Assets and Liabilities:
Accounts Payable to Related Parties	71,251	64,915
Trade Accounts Payable	7,025	14,513
Net Cash Used in Operating Activities	(32,172)	(605)
Cash Flows From Financing Activities
Financing Cost - Proceeds From Borrowing Under Notes Payable to Related Parties	30,791	0
Financing Cost - Interest Payable to Related Parties	1,381	0
Net Cash Provided by Financing Activities	32,172	0
Net Decrease in Cash	0	(605)
Cash and Cash Equivalents at Beginning of Year	0	605
Cash and Cash Equivalents at End of Year	0	0
Supplemental Cash Flow Information
Cash paid for interest	0	0
Cash paid for income taxes	$ 0	$ 0

Note 1 - Basis of Presentation

Note 1 - Basis of Presentation and Significant Accounting Policies	12 Months Ended
	Dec. 31, 2018
Disclosure Text Block [Abstract]
Note 1 - Basis of Presentation and Significant Accounting Policies	NOTE 1 – BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The Company currently is a shell corporation and does not currently have any business or any sources of revenue. The Company wants to acquire all or a portion of one or more operating businesses. Management of the Company currently is exclusively exploring potential acquisitions of all or a portion of one or more operating businesses involving the manufacture and sale of cannabidiol (CBD)-infused products such as beverages, muscle/joint rubs, oils, crystals, tinctures, bath bombs, isolate, relief balms, elixirs, body washes, med sticks, lotions, vape pens and cartridges, shatter, and gummies (a “CBD-Infused Products Company”). In order to consummate a particular acquisition of a CBD-Infused Products Company, management of the Company is open-minded to the concept of also acquiring all or a portion of one or more operating businesses and/or assets that are related to such CBD-Infused Products Company, for example operating businesses and/or assets involving distilled spirits, beer, wine, hemp, paraphernalia, cannabis, tetrahydrocannabinol (THC)-infused products, and real estate. Execution of Stock Purchase Agreement to Purchase up to 19.99% of CBD-Infused Beverage Maker Ablis, and of Craft Distillers Bendistillery and Bend Spirits On February 27, 2019, the Company signed a Stock Purchase Agreement to purchase up to 19.99% of the common stock of CBD-infused beverage maker Ablis Inc. (formerly Ablis LLC) (www.AblisBev.com), and of craft distillers Bendistillery Inc. d/b/a Crater Lake Spirits (www.CraterLakeSpirits.com) and Bend Spirits, Inc. (www.Bendistillery.com), Bend, Oregon, for a total of $7,596,200 in cash. Founded in 1996, Bendistillery is America's most award winning craft distillery, with an outstanding reputation for producing Crater Lake Spirits brands including vodkas, gins, whiskeys, and white label brands offered through Bend Spirits. Ablis is a rapidly growing leader in the exciting CBD-infused beverage industry. Ablis' all-natural, shelf-stable, GMO-free, non-alcoholic, lemon ginger, cranberry blood orange, and 0 calorie lemon water beverages target the mainstream health market and contain no THC. Ablis also manufactures and sells CBD-infused rubs, oils and crystals. Ablis' beverages are now being distributed in 11 states, online throughout the country, Puerto Rico and Guam. Also, Ablis has recently received state approval to co-brand with a local brewery in Bend to produce Oregon's first hemp CBD-infused draft beer. Closing of the purchase is subject to a number of conditions, including the completion of mutually acceptable due diligence, completion of a capital raise, execution of definitive documentation, obtaining necessary third party approvals, and completion of all necessary securities filings. The Company expects to close the purchase in tranches, starting with a first tranche purchase of 4.99% of the common stock of each of Ablis, Bendistillery and Bend Spirits for an aggregate purchase price of $1,896,200. The Company has raised sufficient capital through the sale of convertible preferred stock to allow the Company to close this first tranche purchase, and this first tranche purchase is expected to close during March 2019. Following the expected closing of this first tranche purchase of 4.99% of the common stock of each of Ablis, Bendistillery and Bend Spirits, the Company desires to purchase up to an additional 15% of the common stock of each of Ablis, Bendistillery and Bend Spirits under the Stock Purchase Agreement, but doing so will only be possible if the Company closes on the sale of additional preferred stock or otherwise raises capital, and receives approval to do so from the Oregon Liquor Control Commission. The stock purchase will make capital available for expanded off-line and online advertising, additional staff and equipment, and repayment of debt, for Bendistillery, Bend Spirits, and Ablis. The management teams of Ablis, Bendistillery and Bend Spirits will continue to lead their respective companies following the closing of the transaction. Gerard M. Jacobs, CEO of the Company, will join the board of directors of each of the companies, and William C. Jacobs, CFO of the Company, will be paid quarterly by the companies in regard to financial oversight of the companies. Use of Estimates Cash and Cash Equivalents Fair Value of Financial Instruments Accounting Standards Codification (ASC) 820 defines fair value, establishes a framework for measuring fair value under U.S. GAAP and enhances disclosures about fair value measurements. Fair value is defined under ASC 820 as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value under ASC 820 must maximize the use of observable inputs and minimize the use of unobservable inputs. The standard describes a fair-value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value as follows: Level 1 – Level 2 – Level 3 – Income Taxes Basic and Diluted Earnings (Loss) Per Common Share For the Year Ended December 31, 2018 2017 Net Loss $ (220,621) $ (80,033) Weighted-Average Shares Outstanding 2,369,648 2,369,648 Basic and Diluted Earnings Loss per Share $ (0.09) $ (0.03) At December 31, 2018, there were outstanding options to purchase 1,186,132 shares of common stock at between $0.001 and $0.60 per share, (b) rights to purchase warrants to purchase 2,950,000 shares of common stock at between $0.01 and $1.85 per share, and (c) financing warrants to purchase 37,500 shares of common stock at $0.03. As of the date of this report, none of these outstanding options, rights to purchase warrants or financing warrants have been exercised into shares of common stock. However, all of them may be exercised at any time in the sole discretion of the holder except for the rights to purchase warrants to purchase 1.25 million shares of our commons stock, are not exercisable until a performance contingency is met. In comparison, at December 31, 2017, there were 1,358,774 stock options and rights to purchase warrants to purchase 2,700,000 shares of the Company’s common stock outstanding that were excluded from the computation of diluted earnings loss per share because their effects would have been anti-dilutive. Recent Accounting Pronouncements On January 5, 2017, the FASB issued ASU No. 2017-01, “Clarifying the Definition of a Business” (Topic ASC 805), guidance to clarify the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The amendments in this ASU provide a screen to determine when an integrated set of assets and activities (collectively referred to as a “set”) is not a business. The screen requires that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the set is not a business. This screen reduces the number of transactions that need to be further evaluated. If the screen is not met, the amendments require that to be considered a business, a set must include, at a minimum, an input and a substantive process that together significantly contribute to the ability to create output and remove the evaluation of whether a market participant could replace the missing elements. This ASU is effective for public business entities in annual periods beginning after December 15, 2017, including interim periods therein. We are currently evaluating the impact that this amendment will have on our financial statements. In May 2017, the FASB issued ASU No. 2017-09, “Compensation – Stock Compensation” (Topic 718) - Scope of Modification Accounting. This ASU clarifies when to account for a change to the terms or conditions of a share-based payment award as a modification. Under the new guidance, modification accounting is required only if the fair value, the vesting conditions, or the classification of the award (as equity or liability) changes as a result of the change in terms or conditions. This ASU is effective prospectively for the annual period ending December 31, 2018 and interim periods within that annual period. We are currently evaluating the impact that this amendment will have on our financial statements. In June 2018, the FASB issued ASU No. 2018-07, Compensation – Stock Compensation (Topic 718), Improvements to Nonemployee Share-Based Payment Accounting, which is intended to improve the usefulness of the information provided to the users of financial statements while reducing cost and complexity in financial reporting. Under the new standard, nonemployee share-based payment awards within the scope of Topic 718 are measured at grant-date fair value of the equity instruments that an entity is obligated to issue when conditions necessary to earn the right to benefit from the instruments have been satisfied. These equity-classified non-employee share-based payment awards are measured at the grant date. Consistent with the accounting for employee share-based payment awards, an entity considers the probability of satisfying performance conditions when nonemployee share-based payment awards contain such conditions. The new standard also eliminates the requirement to reassess classification of such awards upon vesting. The new standard is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2018. We are currently evaluating the impact that this amendment will have on our financial statements. Off Balance Sheet Arrangements

Note 2 - Risks and Uncertaintie

Note 2 - Risks and Uncertainties	12 Months Ended
	Dec. 31, 2018
Disclosure Text Block [Abstract]
Note 2 - Risks and Uncertainties	NOTE 2 - RISKS AND UNCERTAINTIES Going Concern – The Company currently is a shell corporation and does not have any business or any sources of revenue. The Company currently has no revenue-generating subsidiaries. Management plans to sustain the Company as a going concern by taking the following actions: (1) acquiring and/or developing profitable businesses that will create positive income from operations; and/or (2) completing private placements of the Company’s common stock and/or preferred stock. Management believes that by taking these actions, the Company will be provided with sufficient future operations and cash flow to continue as a going concern. However, there can be no assurances or guarantees whatsoever that the Company will be successful in consummating such actions on acceptable terms, if at all. Moreover, any such actions can be expected to result in substantial dilution to the existing shareholders of the Company.

Note 3 - Notes Receivable

Note 3 - Notes Receivable	12 Months Ended
	Dec. 31, 2018
Disclosure Text Block [Abstract]
Note 3 - Notes Receivable	NOTE 3 – NOTES RECEIVABLE The William Noyes Webster Foundation, Inc. The Foundation, a non-profit Massachusetts corporation, has received a provisional registration from the Commonwealth of Massachusetts to own and operate a medical marijuana cultivation facility in Plymouth, Massachusetts, and a medical marijuana dispensary in Dennis, Massachusetts. Jane W. Heatley (“Heatley”) is the founder and a member of the board of directors of the Foundation. Teaming Agreement Promissory Note Between April and July 2015, the Company loaned an additional $135,350 to the Foundation, evidenced by the Note and secured by the Security Agreement. Following such additional loans, the principal of the loan from the Company to the Foundation, evidenced by the Note and secured by the Security Agreement, is now $737,850. The principal balance outstanding under the Note bore interest at the rate of 12.5% per annum, compounded monthly. It was contemplated that the first payment of accrued interest by the Foundation under the Note would be made as soon after the Foundation commences operations of the Plymouth Cultivation Facility and the Dennis Dispensary as the Foundation's cash flows shall reasonably permit, but in any event no later than one year after the Foundation commences operations. The principal of the Note would be payable in eight consecutive equal quarterly installments, commencing on the last day of the calendar quarter in which the Foundation commences operations. Principal on the Note and related accrued interest would be considered past due if the aforementioned payments were not received by their due dates. Uncollectable Note and Interest Receivable

Note 4 - Amounts Owed to Relate

Note 4 - Amounts Owed to Related Parties	12 Months Ended
	Dec. 31, 2018
Related Party Transactions [Abstract]
Note 4 - Amounts Owed to Related Parties	NOTE 4 – AMOUNTS OWED TO RELATED PARTIES On June 21, 2016, a company affiliated with Gerard M. Jacobs, Chief Executive Officer of Acquired Sales, made a non-interest bearing loan of $4,000 to the Company, which is payable upon demand. At December 31, 2018, there are expense reimbursements owed to Gerard M. Jacobs totaling $24,583. In comparison, at December 31, 2017, there were expense reimbursements owed to Gerard M. Jacobs totaling $13,841. At December 31, 2018, there are independent contractor fees of $160,000 and expense reimbursements of $4,417 owed to William C. Jacobs totaling $164,417. In comparison, at December 31, 2017, there were independent contractor fees of $100,000 and expense reimbursements of $3,907 owed to William C. Jacobs totaling $103,907. William C. Jacobs is the son of Gerard M. Jacobs, Chief Executive Officer of Acquired Sales, and the nephew of director James S. Jacobs. Financing Warrants As of December 31, 2018, a total of $30,791 has been borrowed by AQSP on such terms, and warrants to purchase 25,000 shares of common stock of AQSP have been issued to Joshua A. Bloom and warrants to purchase 12,500 shares of common stock of AQSP have been issued to Gerard M. Jacobs. The warrants to purchase common stock that were issued to Joshua A. Bloom and Gerard M. Jacobs on July 16, 2018 and July 18, 2018 were valued using the Black-Scholes valuation model as of the date they were issued. The values of these warrants were fully expensed because the notes are payable upon demand. The expense recognized related to the issuance of the warrants to Joshua A. Bloom on July 16, 2018 was $3,250. Gerard M. Jacobs’ warrants were issued to him on July 18, 2018, and the expense recognized related to the issuance of these warrants was $1,300. The warrants to purchase common stock that were issued to Gerard M. Jacobs on November 8, 2018, and to Joshua A. Bloom on November 12, 2018, were valued using the Black-Scholes valuation model, which incorporated the following assumptions: expected future stock volatility 465%; risk-free interest rates of 2.98% and 2.94%, respectively; dividend yield of 0% and an expected terms of 2.38 years and 2.37 years, respectively. The expected future stock volatility was based on the volatility of Acquired Sales Corp.’s historical stock prices. The risk-free interest rate was based on the U.S. Federal treasury rate for instruments due over the expected term of the warrants. The expected term of each warrant was based on the midpoint between the date the warrant vests and the contractual term of the warrant. The values of the warrants were fully expensed as of the date of issuance because they are payable upon demand. The expense recognized related to the issuance of the warrants to Gerard M. Jacobs on November 8, 2018 was $11,250. The expense recognized related to the issuance of the warrants to Joshua A. Bloom on November 12, 2018 was $21,874.

Note 5 - Shareholders' Equity

Note 5 - Shareholders' Equity	12 Months Ended
	Dec. 31, 2018
Disclosure Text Block [Abstract]
Note 5 - Shareholders' Equity	NOTE 5 – SHAREHOLDERS’ EQUITY Share-Based Compensation The following is a summary of share-based compensation, stock option and warrant activity as of December 31, 2018 and changes during the year then ended: Shares Weighted-Average Exercise Price (a) Weighted-Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding, December 31, 2017 4,058,774 $ 1.29 5.59 $ 577,725 Rights to Purchase Warrants Issued During Period 250,000 Financing Warrants Issued During Period 37,500 Options Expired During Period 172,642 Options, Rights to Purchase Warrants and Financing Warrants Outstanding, December 31, 2018 4,173,632 $ 1.16 4.95 $ 2,410,100 Exercisable Options, Rights to Purchase Warrants and Financing Warrants Outstanding, December 31, 2018 2,923,632 $ 0.87 4.93 $ 2,410,100 Note: (a) The Weighted-Average Exercise Price column excludes those warrants that have an exercise price for the common stock priced at the Capital Raise Price Per Share. Rights to Purchase Warrants Issued During Period total stock compensation expense of $72,500 related to these rights to purchase warrants; this consists of $11,600 of stock compensation for the rights to purchase warrants issued to James S. Jacobs, and $60,900 of stock compensation for the rights to purchase warrants issued to William C. Jacobs. On October 1, 2018, William C. Jacobs assigned rights to purchase warrants to purchase 10,000 shares of common stock to a separate entity.

Note 6 - Income Taxes

Note 6 - Income Taxes	12 Months Ended
	Dec. 31, 2018
Disclosure Text Block [Abstract]
Note 6 - Income Taxes	NOTE 6 – INCOME TAXES On December 22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act (the “Tax Act”). The Tax Act reduced the U.S. federal statutory tax rate, broadened the corporate tax base through the elimination or reduction of deductions, exclusions, and credits, limited the ability of U.S. corporations to deduct interest expense, and transitioned to a territorial tax system which allows for the repatriation of foreign earnings to the U.S. with a 100% federal dividends received deduction prospectively. In addition, the Tax Act required a one-time transitional tax on foreign cash equivalents and previously unremitted earnings. Several of the new provisions enacted as part of the Tax Act require clarification and guidance from the U.S. Internal Revenue Service (“IRS”) and Treasury Department. These or other changes in U.S. tax laws could impact our profits, effective tax rate, and cash flows. During the years ended December 31, 2018 and 2017, the Company did not incur any current tax on its continuing operations and there was no deferred tax provision or benefit from continuing operations. At December 31, 2018, the Company has U.S. Federal net operating loss carry forwards of $2,115,050 that will expire in 2030 through 2034 if not used by those dates. As of December 31, 2018, the Company had no unrecognized tax benefits that, if recognized, would affect the Company’s effective income tax rate over the next 12 months. The Company currently believes that all significant filing positions are highly certain and that all of its significant income tax filing positions and deductions would be sustained upon audit. Therefore, the Company has no significant reserves for uncertain tax positions and no adjustments to such reserves were required by generally accepted accounting principles. The Company’s policy is to recognize accrued interest and penalties related to unrecognized tax benefits in the provision for income taxes. The Company’s tax returns are subject to examination for the years ended December 31, 2013 through 2017. A reconciliation of the amount of tax benefit computed using the U.S. federal statutory income tax rate to the provision for income taxes on continuing operations is as follows: For the Years Ended December 31, 2018 2017 Tax expenses (benefit) at statutory rate (21%) $ (46,330) $ (27,211) State tax benefit, net of federal benefit $ - (2,641) Non-deductible expenses $ 276 40 Revision of prior years' deferred tax assets $ (30,034) 67,252 Change in valuation allowance $ (1,488,585) (37,439) Provision for Income Taxes $ - $ - The tax effects of temporary differences and carry forwards that gave rise to the net deferred income tax asset as of December 31, 2018 and 2017 were as follows: December 31, 2018 2017 Operating loss carry forwards $ 428,393 $ 676,116 Stock-based compensation 1,633,366 2,874,127 Other 131 233 Less: Valuation allowance (2,061,891) (3,550,475) Net Deferred Income Tax Asset $ - $ - The deferred tax asset valuation allowance decreased by $1,488,585 and $37,439 during the years ended December 31, 2018 and 2017, respectively.

Note 7 - Contingent Contractual

Note 7 - Contingent Contractual Obligations and Commercial Commitments	12 Months Ended
	Dec. 31, 2018
Disclosure Text Block [Abstract]
Note 7 - Contingent Contractual Obligations and Commercial Commitments	NOTE 7 – CONTINGENT CONTRACTUAL OBLIGATIONS AND COMMERCIAL COMMITMENTS The Board of Directors of the Company has committed to pay compensation to Gerard M. Jacobs, our Chief Executive Officer, as an inducement to him to introduce attractive acquisitions to the Company. The amount of the compensation will be 10% of the consideration paid by the Company to acquire equity ownership interests in target companies. The timing and structure of such compensation is currently expected to be determined pursuant to negotiations to be held between Gerard M. Jacobs and the chairman of the Compensation Committee of the Board of Directors.

Note 8 - Subsequent Events

Note 8 - Subsequent Events	12 Months Ended
	Dec. 31, 2018
Subsequent Events [Abstract]
Note 8 - Subsequent Events	NOTE 8 – SUBSEQUENT EVENTS Additional Borrowings in Exchange for Notes, Accrued Interest and Financing Warrants On July 13, 2018, the Audit Committee, Compensation Committee, and full Board of Directors of AQSP approved by unanimous written consent borrowings by AQSP on the following terms: (1) proceeds of the borrowings will be used to pay professional fees owed to our outside auditors, our stock transfer agent, and our securities counsel, and to pay other obligations of AQSP; (2) the borrowings will be evidenced by promissory notes of AQSP, accruing interest at the rate of 15% annually; (3) the notes will be jointly secured by a first lien security interest in all of the assets of AQSP, pursuant to a security agreement signed by AQSP in favor of the lenders, UCC filings in favor of the lenders, and a pledge to the lenders of the note payable by the William Noyes Webster Foundation Inc. to AQSP; (4) the notes shall be due and payable upon demand by the lenders delivered to AQSP; and (5) for each $1,000 loaned by AQSP on these terms, the lender of such $1,000 shall receive warrants to purchase 1,250 shares of common stock of AQSP, at an exercise price of $0.03 per share, exercisable at the discretion of such lender any time on or before July 16, 2023. During the year ended December 31, 2018, $30,791 was borrowed on these terms. Following the end of the period ended December 31, 2018, a total of $14,772 has been borrowed by AQSP on such terms. Signing of a Definitive Stock Purchase Agreement with Ablis, Bendistillery and Bend Spirits On February 27, 2019, the Company signed a definitive Stock Purchase Agreement (the "SPA") with Ablis, Bendistillery, Bend Spirits, Bendis Homes Pinehurst, LLC, James A. Bendis, Alan T. Dietrich, Gerard M. Jacobs and William C. "Jake" Jacobs to purchase 4.99% of the common stock of Ablis for $399,200 in cash, to purchase 4.99% of the common stock of Bendistillery for $1,347,300 in cash, and to purchase 4.99% of the common stock of Bend Spirits for $149,700 in cash. The purchases are expected to close during March 2019. Under the SPA the Company will have the right to purchase up to an additional 15% of the common stock of each of Ablis, Bendistillery and Bend Spirits. Acceptance of Subscriptions From Accredited Investors to Purchase Newly Issued Series A Convertible Preferred Stock On February 27, 2019, the Company accepted subscriptions from accredited investors to purchase 23,400 shares of newly issued Series A Convertible Preferred Stock ("Preferred Stock") for an aggregate purchase price of $2,340,000 in cash. These 23,400 shares of Preferred Stock are convertible at the option of the holders into 2,340,000 shares of newly issued common stock of the Company, or $1.00 per share of common stock of the Company. The Company has committed to file a registration statement covering the shares of newly issued common stock of the Company into which the Preferred Stock can be converted (the "Registration Statement"). The Preferred Stock will receive an annual dividend, and will be subject to mandatory conversion, under terms and conditions set forth in the Certificate of Designation of the Preferred Stock. Newly Elected Director of the Company: Thomas W. Hines, CPA CFA Thomas W. Hines, CPA CFA, a Vice President of Lowery Asset Consulting in Chicago, has been elected to serve as a Director of the Company. William C. "Jake" Jacobs, CPA: Elected to serve as the President, Chief Financial Officer and Treasurer of the Company William C. "Jake" Jacobs, CPA, the son of our Company's Chief Executive Officer Gerard M. Jacobs, has been elected to serve as the President, Chief Financial Officer and Treasurer of the Company. Gerard M. Jacobs will remain as the Company's Chairman, Chief Executive Officer and Secretary. Establishment of an Investment Committee The Board of Directors of the Company has voted to establish an Investment Committee, the initial members of which will be Gerard M. Jacobs, William C. "Jake" Jacobs, CPA, and Thomas W. Hines, CPA CFA. Future acquisitions by the Company of direct equity ownership interests in any entity other than Ablis, Bendistillery and Bend Spirits will be subject to unanimous approval by such Investment Committee and to majority approval by the Board of Directors of the Company, provided that the requirement of unanimous approval by such Investment Committee will be terminated if the investors in the Preferred Stock no longer hold 25% or more of their investment in the form of Preferred Stock or common stock of the Company following conversion, or if the Company's common stock has closed at $10.00 per share or higher for 20 consecutive trading days and there have been on average at least 50,000 shares traded on each of those 20 consecutive trading days, or if 84 months have passed since the first date that the Registration Statement is effective.

Note 1 - Basis of Presentatio_2

Note 1 - Basis of Presentation and Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2018
Policy Text Block [Abstract]
Basis of Presentation	Basis of Presentation Basis of Presentation The Company currently is a shell corporation and does not currently have any business or any sources of revenue. The Company wants to acquire all or a portion of one or more operating businesses. Management of the Company currently is exclusively exploring potential acquisitions of all or a portion of one or more operating businesses involving the manufacture and sale of cannabidiol (CBD)-infused products such as beverages, muscle/joint rubs, oils, crystals, tinctures, bath bombs, isolate, relief balms, elixirs, body washes, med sticks, lotions, vape pens and cartridges, shatter, and gummies (a “CBD-Infused Products Company”). In order to consummate a particular acquisition of a CBD-Infused Products Company, management of the Company is open-minded to the concept of also acquiring all or a portion of one or more operating businesses and/or assets that are related to such CBD-Infused Products Company, for example operating businesses and/or assets involving distilled spirits, beer, wine, hemp, paraphernalia, cannabis, tetrahydrocannabinol (THC)-infused products, and real estate. Execution of Stock Purchase Agreement to Purchase up to 19.99% of CBD-Infused Beverage Maker Ablis, and of Craft Distillers Bendistillery and Bend Spirits On February 27, 2019, the Company signed a Stock Purchase Agreement to purchase up to 19.99% of the common stock of CBD-infused beverage maker Ablis Inc. (formerly Ablis LLC) (www.AblisBev.com), and of craft distillers Bendistillery Inc. d/b/a Crater Lake Spirits (www.CraterLakeSpirits.com) and Bend Spirits, Inc. (www.Bendistillery.com), Bend, Oregon, for a total of $7,596,200 in cash. Founded in 1996, Bendistillery is America's most award winning craft distillery, with an outstanding reputation for producing Crater Lake Spirits brands including vodkas, gins, whiskeys, and white label brands offered through Bend Spirits. Ablis is a rapidly growing leader in the exciting CBD-infused beverage industry. Ablis' all-natural, shelf-stable, GMO-free, non-alcoholic, lemon ginger, cranberry blood orange, and 0 calorie lemon water beverages target the mainstream health market and contain no THC. Ablis also manufactures and sells CBD-infused rubs, oils and crystals. Ablis' beverages are now being distributed in 11 states, online throughout the country, Puerto Rico and Guam. Also, Ablis has recently received state approval to co-brand with a local brewery in Bend to produce Oregon's first hemp CBD-infused draft beer. Closing of the purchase is subject to a number of conditions, including the completion of mutually acceptable due diligence, completion of a capital raise, execution of definitive documentation, obtaining necessary third party approvals, and completion of all necessary securities filings. The Company expects to close the purchase in tranches, starting with a first tranche purchase of 4.99% of the common stock of each of Ablis, Bendistillery and Bend Spirits for an aggregate purchase price of $1,896,200. The Company has raised sufficient capital through the sale of convertible preferred stock to allow the Company to close this first tranche purchase, and this first tranche purchase is expected to close during March 2019. Following the expected closing of this first tranche purchase of 4.99% of the common stock of each of Ablis, Bendistillery and Bend Spirits, the Company desires to purchase up to an additional 15% of the common stock of each of Ablis, Bendistillery and Bend Spirits under the Stock Purchase Agreement, but doing so will only be possible if the Company closes on the sale of additional preferred stock or otherwise raises capital, and receives approval to do so from the Oregon Liquor Control Commission. The stock purchase will make capital available for expanded off-line and online advertising, additional staff and equipment, and repayment of debt, for Bendistillery, Bend Spirits, and Ablis. The management teams of Ablis, Bendistillery and Bend Spirits will continue to lead their respective companies following the closing of the transaction. Gerard M. Jacobs, CEO of the Company, will join the board of directors of each of the companies, and William C. Jacobs, CFO of the Company, will be paid quarterly by the companies in regard to financial oversight of the companies.
Use of Estimates	Use of Estimates
Cash and Cash Equivalents	Cash and Cash Equivalents
Fair Value of Financial Instruments	Fair Value of Financial Instruments Accounting Standards Codification (ASC) 820 defines fair value, establishes a framework for measuring fair value under U.S. GAAP and enhances disclosures about fair value measurements. Fair value is defined under ASC 820 as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value under ASC 820 must maximize the use of observable inputs and minimize the use of unobservable inputs. The standard describes a fair-value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value as follows: Level 1 – Level 2 – Level 3 –
Income Taxes	Income Taxes
Basic and Diluted Earnings (Loss) Per Common Share	Basic and Diluted Earnings (Loss) Per Common Share For the Year Ended December 31, 2018 2017 Net Loss $ (220,621) $ (80,033) Weighted-Average Shares Outstanding 2,369,648 2,369,648 Basic and Diluted Earnings Loss per Share $ (0.09) $ (0.03) At December 31, 2018, there were outstanding options to purchase 1,186,132 shares of common stock at between $0.001 and $0.60 per share, (b) rights to purchase warrants to purchase 2,950,000 shares of common stock at between $0.01 and $1.85 per share, and (c) financing warrants to purchase 37,500 shares of common stock at $0.03. As of the date of this report, none of these outstanding options, rights to purchase warrants or financing warrants have been exercised into shares of common stock. However, all of them may be exercised at any time in the sole discretion of the holder except for the rights to purchase warrants to purchase 1.25 million shares of our commons stock, are not exercisable until a performance contingency is met. In comparison, at December 31, 2017, there were 1,358,774 stock options and rights to purchase warrants to purchase 2,700,000 shares of the Company’s common stock outstanding that were excluded from the computation of diluted earnings loss per share because their effects would have been anti-dilutive.
Recent Accounting Pronouncements	Recent Accounting Pronouncements On January 5, 2017, the FASB issued ASU No. 2017-01, “Clarifying the Definition of a Business” (Topic ASC 805), guidance to clarify the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The amendments in this ASU provide a screen to determine when an integrated set of assets and activities (collectively referred to as a “set”) is not a business. The screen requires that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the set is not a business. This screen reduces the number of transactions that need to be further evaluated. If the screen is not met, the amendments require that to be considered a business, a set must include, at a minimum, an input and a substantive process that together significantly contribute to the ability to create output and remove the evaluation of whether a market participant could replace the missing elements. This ASU is effective for public business entities in annual periods beginning after December 15, 2017, including interim periods therein. We are currently evaluating the impact that this amendment will have on our financial statements. In May 2017, the FASB issued ASU No. 2017-09, “Compensation – Stock Compensation” (Topic 718) - Scope of Modification Accounting. This ASU clarifies when to account for a change to the terms or conditions of a share-based payment award as a modification. Under the new guidance, modification accounting is required only if the fair value, the vesting conditions, or the classification of the award (as equity or liability) changes as a result of the change in terms or conditions. This ASU is effective prospectively for the annual period ending December 31, 2018 and interim periods within that annual period. We are currently evaluating the impact that this amendment will have on our financial statements. In June 2018, the FASB issued ASU No. 2018-07, Compensation – Stock Compensation (Topic 718), Improvements to Nonemployee Share-Based Payment Accounting, which is intended to improve the usefulness of the information provided to the users of financial statements while reducing cost and complexity in financial reporting. Under the new standard, nonemployee share-based payment awards within the scope of Topic 718 are measured at grant-date fair value of the equity instruments that an entity is obligated to issue when conditions necessary to earn the right to benefit from the instruments have been satisfied. These equity-classified non-employee share-based payment awards are measured at the grant date. Consistent with the accounting for employee share-based payment awards, an entity considers the probability of satisfying performance conditions when nonemployee share-based payment awards contain such conditions. The new standard also eliminates the requirement to reassess classification of such awards upon vesting. The new standard is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2018. We are currently evaluating the impact that this amendment will have on our financial statements.
Off Balance Sheet Arrangements	Off Balance Sheet Arrangements

Note 1 - Basis of Presentatio_3

Note 1 - Basis of Presentation and Significant Accounting Policies: Basic and Diluted Earnings (Loss) Per Common Share: Schedule of Earnings Per Share, Basic and Diluted (Tables)	12 Months Ended
	Dec. 31, 2018
Table Text Block Supplement [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	The following table summarizes the calculations of basic and diluted earnings (loss) per common share for the years ended December 31, 2018 and 2017: For the Year Ended December 31, 2018 2017 Net Loss $ (220,621) $ (80,033) Weighted-Average Shares Outstanding 2,369,648 2,369,648 Basic and Diluted Earnings Loss per Share $ (0.09) $ (0.03)

Note 5 - Shareholders' Equity_

Note 5 - Shareholders' Equity: Schedule of Share-based Compensation, Stock Options and Warrant Activity (Tables)	12 Months Ended
	Dec. 31, 2018
Table Text Block Supplement [Abstract]
Schedule of Share-based Compensation, Stock Options and Warrant Activity	The following is a summary of share-based compensation, stock option and warrant activity as of December 31, 2018 and changes during the year then ended: Shares Weighted-Average Exercise Price (a) Weighted-Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Outstanding, December 31, 2017 4,058,774 $ 1.29 5.59 $ 577,725 Issued During Period 250,000 Expired During Period 172,642 Outstanding, September 30, 2018 4,136,132 $ 1.17 4.96 $ 2,356,475 Exercisable, September 30, 2018 2,886,132 $ 0.88 4.93 $ 2,356,475 Note: (a) The Weighted-Average Exercise Price column excludes those warrants that have an exercise price for the common stock priced at the Capital

Note 6 - Income Taxes_ Schedule

Note 6 - Income Taxes: Schedule of Effective Income Tax Rate Reconciliation (Tables)	12 Months Ended
	Dec. 31, 2018
Table Text Block Supplement [Abstract]
Schedule of Effective Income Tax Rate Reconciliation	A reconciliation of the amount of tax benefit computed using the U.S. federal statutory income tax rate to the provision for income taxes on continuing operations is as follows: For the Years Ended December 31, 2018 2017 Tax expenses (benefit) at statutory rate (21%) $ (46,330) $ (27,211) State tax benefit, net of federal benefit $ - (2,641) Non-deductible expenses $ 276 40 Revision of prior years' deferred tax assets $ (30,034) 67,252 Change in valuation allowance $ (1,488,585) (37,439) Provision for Income Taxes $ - $ -

Note 6 - Income Taxes_ Schedu_2

Note 6 - Income Taxes: Schedule of Deferred Tax Assets (Tables)	12 Months Ended
	Dec. 31, 2018
Table Text Block Supplement [Abstract]
Schedule of Deferred Tax Assets	The tax effects of temporary differences and carry forwards that gave rise to the net deferred income tax asset as of December 31, 2018 and 2017 were as follows: December 31, 2018 2017 Operating loss carry forwards $ 428,393 $ 676,116 Stock-based compensation 1,633,366 2,874,127 Other 131 233 Less: Valuation allowance (2,061,891) (3,550,475) Net Deferred Income Tax Asset $ - $ -

Note 1 - Basis of Presentatio_4

Note 1 - Basis of Presentation and Significant Accounting Policies: Basic and Diluted Earnings (Loss) Per Common Share: Schedule of Earnings Per Share, Basic and Diluted (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Text Block [Abstract]
Net Loss	$ (220,621)	$ (80,033)
Weighted Average Shares Outstanding	2,369,648	2,369,648
Basic and Diluted Earnings Loss per Share	$ (0.09)	$ (0.03)

Note 1 - Basis of Presentatio_5

Note 1 - Basis of Presentation and Significant Accounting Policies: Basic and Diluted Earnings (Loss) Per Common Share (Details) - shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Stock Option
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1,186,132	1,358,774
Warrant
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	2,950,000	2,700,000
Financing Warrant
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	37,500

Note 2 - Risks and Uncertaint_2

Note 2 - Risks and Uncertainties (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Text Block [Abstract]
Accumulated deficit	$ (14,005,689)	$ (13,785,068)
Net Loss	$ (220,621)	$ (80,033)

Note 3 - Notes Receivable (Deta

Note 3 - Notes Receivable (Details) - USD ($)	Sep. 01, 2015	Jul. 31, 2015	Jul. 31, 2016	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2015	Dec. 31, 2016	Jul. 14, 2015
Bad debt expense				$ 0	$ 835,277
Secured Promissory Note | William Noyes Webster Foundation Inc
Debt Instrument, Face Amount								$ 1,500,000
Note receivable payment		$ 602,500	$ 135,350
Advances		600,000
Note Receivable							$ 737,850
Debt Instrument, Interest Rate, Stated Percentage							12.50%
Bad debt expense	$ 737,850
Secured Promissory Note | One-Seven LLC
Note receivable payment						$ 25,000
Debt Instrument, Description						In consideration of such $50,000 loan to One-Seven, One-Seven and Stukel agreed that if One-Seven is successful in securing additional funding, then Stukel and One-Seven are obligated to use good faith efforts to work with Gerard M. Jacobs and the Company, as a team and not as a partnership, joint venture or other entity, in order to explore and hopefully close transactions pursuant to which: (a) One-Seven may provide debt, convertible debt and/or equity to the Company, all on mutually acceptable terms and conditions; (b) One-Seven may provide debt, convertible debt and/or equity to business entities that may be wholly or partly purchased by, or merged into, the Company, all on mutually acceptable terms and conditions; and (c) Stukel may participate in the management of the Company and obtain a salary and a package of stock options and/or warrants to purchase shares of common stock of the Company, all on mutually acceptable terms and conditions.
Interest receivable {1} | William Noyes Webster Foundation Inc
Bad debt expense	$ 97,427
Payment To Consultant | Secured Promissory Note | William Noyes Webster Foundation Inc
Advances		$ 2,500
Unfunded Portion of Note | Secured Promissory Note | William Noyes Webster Foundation Inc
Debt Instrument, Face Amount								$ 897,500

Note 4 - Amounts Owed To Rela_2

Note 4 - Amounts Owed To Related Parties (Details) - USD ($)	Nov. 12, 2018	Nov. 08, 2018	Jul. 13, 2018	Jul. 23, 2018	Jul. 18, 2018	Jul. 16, 2018	Dec. 31, 2018	Dec. 31, 2017	Jun. 21, 2016
Debt Instrument, Payment Terms				(1) proceeds of the borrowings will be used to pay professional fees owed to our outside auditors, our stock transfer agent, and our securities counsel, and to pay other obligations of AQSP; (2) the borrowings will be evidenced by promissory notes of AQSP, accruing interest at the rate of 15% annually; (3) the notes will be jointly secured by a first lien security interest in all of the assets of AQSP, pursuant to a security agreement signed by AQSP in favor of the lenders, UCC filings in favor of the lenders, and a pledge to the lenders of the note payable by the William Noyes Webster Foundation Inc. to AQSP; (4) the notes shall be due and payable upon demand by the lenders delivered to AQSP; and (5) for each $1,000 loaned by AQSP on these terms, the lender of such $1,000 shall receive warrants to purchase 1,250 shares of common stock of AQSP, at an exercise price of $0.03 per share, exercisable at the discretion of such lender any time on or before July 16, 2023.
Long-term Debt, Gross							$ 30,791
Issuance of warrants to purchase common stock							37,673
Gerard M. Jacobs
Due to Other Related Parties, Current									$ 4,000
Due to Related Parties, Current							$ 24,583	$ 13,841
Volatility rate							465.00%
Risk-free interest rates							2.98%
Dividend yield							0.00%
Expected terms							2 years 4 months 17 days
Joshua A. Bloom
Volatility rate							465.00%
Risk-free interest rates							2.94%
Dividend yield							0.00%
Expected terms							2 years 4 months 13 days
William C. Jacobs
Due to Related Parties, Current							$ 164,417	103,907
William C. Jacobs | Independent contractor fees
Due to Related Parties, Current							160,000	100,000
William C. Jacobs | Expense reimbursements
Due to Related Parties, Current							4,417	$ 3,907
Warrant 1 | Gerard M. Jacobs
Warrants issued					12,500
Issuance of warrants to purchase common stock		$ 11,250			$ 1,300
Warrant 1 | Joshua A. Bloom
Warrants issued						25,000
Issuance of warrants to purchase common stock	$ 21,874					$ 3,250
Financing warrants
Debt Instrument, Payment Terms			(1) proceeds of the borrowings will be used to pay professional fees owed to our outside auditors, our stock transfer agent, and our securities counsel, and to pay other obligations of AQSP; (2) the borrowings will be evidenced by promissory notes of AQSP, accruing interest at the rate of 15% annually; (3) the notes will be jointly secured by a first lien security interest in all of the assets of AQSP, pursuant to a security agreement signed by AQSP in favor of the lenders, UCC filings in favor of the lenders, and a pledge to the lenders of the note payable by the William Noyes Webster Foundation Inc. to AQSP; (4) the notes shall be due and payable upon demand by the lenders delivered to AQSP; and (5) for each $1,000 loaned by AQSP on these terms, the lender of such $1,000 shall receive warrants to purchase 1,250 shares of common stock of AQSP, at an exercise price of $0.03 per share, exercisable at the discretion of such lender any time on or before July 16, 2023.
Long-term Debt, Gross							$ 30,791

Note 5 - Shareholders' Equity (

Note 5 - Shareholders' Equity (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Apr. 01, 2018
Stock compensation expense	$ 72,500	$ 0
Class of Warrant, Outstanding			250,000
Purchase price per share			$ 2
William C. Jacobs
Class of Warrant, Outstanding			210,000
Class of Warrant, Exercise Price of Warrants			$ 0.01
James S. Jacobs
Stock compensation expense	11,600
Class of Warrant, Outstanding			40,000
Class of Warrant, Exercise Price of Warrants			$ 0.01
Joshua A. Bloom
Stock compensation expense	$ 60,900
Purchase of warrants	10,000

Note 5 - Shareholders' Equity_2

Note 5 - Shareholders' Equity: Schedule of Share-based Compensation, Stock Options and Warrant Activity (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Text Block [Abstract]
Options, Outstanding, Beginning Balance	4,058,774
Rights to Purchase Warrants Issued During Period	250,000
Financing Warrants Issued During Period	37,500
Shares, expired	172,642
Options, Rights to Purchase Warrants and Financing Warrants Outstanding, Ending Balance	4,173,632	4,058,774
Exercisable Options, Rights to Purchase Warrants and Financing Warrants Outstanding	2,923,632
Options, Rights to Purchase Warrants and Financing Warrants Outstanding, Weighted Average Exercise Price, Beginning Balance	$ 1.29
Options, Rights to Purchase Warrants and Financing Warrants Outstanding, Weighted Average Exercise Price, Ending Balance	1.17	$ 1.29
Exercisable Options, Rights to Purchase Warrants and Financing Warrants, Weighted Average Exercise Price	$ 0.87
Options, Outstanding, Weighted Average Remaining Term	4 years 11 months 12 days	5 years 7 months 2 days
Options, Rights to Purchase Warrants and Financing Warrants Outstanding, Weighted Average Remaining Term	4 years 11 months 4 days
Options, Outstanding, Intrinsic Value, Beginning Balance	$ 577,725
Options, Outstanding, Intrinsic Value, Ending Balance	2,410,100	$ 577,725
Exercisable Options, Rights to Purchase Warrants and Financing Warrants, Intrinsic Value	$ 2,410,100

Note 6 - Income Taxes (Details)

Note 6 - Income Taxes (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Net Operating Loss Carryforwards	$ 2,115,050
Valuation Allowance, Deferred Tax Asset, Decrease Amount	$ 1,488,585	$ 37,439
Minimum
Operating Loss Carryforwards, Expiration Date	Dec. 31, 2030
Maximum
Operating Loss Carryforwards, Expiration Date	Dec. 31, 2034

Note 6 - Income Taxes_ Schedu_3

Note 6 - Income Taxes: Schedule of Effective Income Tax Rate Reconciliation (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Text Block [Abstract]
Tax expenses (benefit) at statutory rate (42%)	$ (46,330)	$ (27,211)
State tax benefit, net of federal benefit	0	(2,641)
Non-deductible expenses	276	40
Revision of prior years' deferred tax assets	(30,034)	67,252
Change in valuation allowance	(1,488,585)	(37,439)
Provision for Income Taxes	$ 0	$ 0

Note 6 - Income Taxes_ Schedu_4

Note 6 - Income Taxes: Schedule of Deferred Tax Assets (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Text Block [Abstract]
Operating loss carry forwards	$ 428,393	$ 676,116
Stock-based compensation	1,633,366	2,874,127
Other	131	233
Less: Valuation allowance	(2,061,891)	(3,550,475)
Net Deferred Income Tax Asset	$ 0	$ 0

Note 7 - Contingent Contractu_2

Note 7 - Contingent Contractual Obligations and Commercial Commitments (Details)	12 Months Ended
	Dec. 31, 2018
Text Block [Abstract]
Commitments description	The amount of the compensation will be 10% of the consideration paid by the Company to acquire equity ownership interests in target companies.

Note 8 - Subsequent Events (Det

Note 8 - Subsequent Events (Details)	1 Months Ended		12 Months Ended
	Feb. 27, 2019USD ($)	Jul. 23, 2018	Dec. 31, 2018USD ($)
Debt Instrument, Payment Terms		(1) proceeds of the borrowings will be used to pay professional fees owed to our outside auditors, our stock transfer agent, and our securities counsel, and to pay other obligations of AQSP; (2) the borrowings will be evidenced by promissory notes of AQSP, accruing interest at the rate of 15% annually; (3) the notes will be jointly secured by a first lien security interest in all of the assets of AQSP, pursuant to a security agreement signed by AQSP in favor of the lenders, UCC filings in favor of the lenders, and a pledge to the lenders of the note payable by the William Noyes Webster Foundation Inc. to AQSP; (4) the notes shall be due and payable upon demand by the lenders delivered to AQSP; and (5) for each $1,000 loaned by AQSP on these terms, the lender of such $1,000 shall receive warrants to purchase 1,250 shares of common stock of AQSP, at an exercise price of $0.03 per share, exercisable at the discretion of such lender any time on or before July 16, 2023.
Long Term Debt, Gross			$ 30,791
Loan Increase			$ 14,772
Subsequent Event | Accredited Investors
Acceptance of Subscriptions Description	On February 27, 2019, the Company accepted subscriptions from accredited investors to purchase 23,400 shares of newly issued Series A Convertible Preferred Stock ("Preferred Stock") for an aggregate purchase price of $2,340,000 in cash. These 23,400 shares of Preferred Stock are convertible at the option of the holders into 2,340,000 shares of newly issued common stock of the Company, or $1.00 per share of common stock of the Company.
Stock Purchase Agreement | Subsequent Event | Ablis
Percntage of common stock purchase	0.0499
Common stock issued for cash	$ 399,200
Stock Purchase Agreement | Subsequent Event | Bendistillery
Percntage of common stock purchase	0.0499
Common stock issued for cash	$ 347,300
Stock Purchase Agreement | Subsequent Event | Bend Spirits
Percntage of common stock purchase	0.0499
Common stock issued for cash	$ 149,700